Nothing Special   »   [go: up one dir, main page]

Reardon et al., 2011 - Google Patents

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma

Reardon et al., 2011

View HTML
Document ID
14154995356200437653
Author
Reardon D
Turner S
Peters K
Desjardins A
Gururangan S
Sampson J
McLendon R
Herndon J
Jones L
Kirkpatrick J
Friedman A
Vredenburgh J
Bigner D
Friedman H
Publication year
Publication venue
Journal of the National Comprehensive Cancer Network

External Links

Snippet

Glioblastoma, the most common primary malignant brain tumor among adults, is a highly angiogenic and deadly tumor. Angiogenesis in glioblastoma, driven by hypoxia-dependent and independent mechanisms, is primarily mediated by vascular endothelial growth factor …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Similar Documents

Publication Publication Date Title
Reardon et al. A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma
Patel et al. Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy
Sia et al. VEGF signaling in cancer treatment
Prenen et al. Tumor-associated macrophages: a short compendium
Niu et al. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy
Tawbi et al. New era in the management of melanoma brain metastases
Faget et al. Neutrophils in the era of immune checkpoint blockade
Lu-Emerson et al. Lessons from anti–vascular endothelial growth factor and anti–vascular endothelial growth factor receptor trials in patients with glioblastoma
Clarke et al. Understanding and targeting resistance to anti-angiogenic therapies
Sathornsumetee et al. Designer therapies for glioblastoma multiforme
Patel et al. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions
Tugues et al. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer
Rapisarda et al. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies
Bottsford-Miller et al. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies
Masoumi Moghaddam et al. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer
Argyriou et al. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas
Chi et al. Inhibition of angiogenesis and invasion in malignant gliomas
Bando Vascular endothelial growth factor and bevacitumab in breast cancer
Sathornsumetee et al. Antiangiogenic therapy in malignant glioma: promise and challenge
Lee et al. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer
Venur et al. Systemic therapy for brain metastases
Bilusic et al. Anti-angiogenesis in prostate cancer: knocked down but not out
CN113939309A (en) Treatment of cancer with sEphB4-HSA fusion protein
Sie et al. Anti-angiogenic therapy in pediatric brain tumors: an effective strategy?
Brastianos et al. Vascular endothelial growth factor inhibitors in malignant gliomas